comparemela.com

Latest Breaking News On - Kelsey kirk - Page 4 : comparemela.com

argenx to Present at Upcoming Investor Conferences

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

New yorkUnited statesNetherlands generalPalos verdesKelsey kirkMichelle greenblattBeth delgiaccoSecurities life sciences conferenceGoldman sachsImmunology innovation programAnnual global healthcareRancho palos verdesLife sciencesGlobe newswire

argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United kingdomKelsey kirkMichelle greenblattBeth delgiaccoSociety for investigative dermatologyImmunology innovation programInvestigative dermatologyAnnual meetingbeingDesmoglein specificb cellsSecondary analysisPemphigus vulgarisAnnual meetingBritish journalHans de haardChief scientific officerPublished translational data

argenx announces results of Annual General Meeting of Shareholders

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Kelsey kirkMichelle greenblattBeth delgiaccoPeter verhaegheJim dalyTim van hauwermeirenWerner lanthalerImmunology innovation programAnnual general meetingVan hauwermeirenGlobe newswireBoard of directorsArgenx se

argenx Reports First Quarter 2022 Financial Results and Provides Business Update

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesUnited kingdomBruxelles capitaleKelsey kirkMichelle greenblattBeth delgiaccoTim van hauwermeirenInternational congress on neuromuscular diseasesEuropean medicines agency on marketing authorization applicationEuropean academy of neurologyZai labDrug administrationSociety for investigative dermatology annual meetingEfgartigimod researchNational health insuranceMeeting of the japanese society neurology

Argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo ; responders observed across patient types regardless of prior. | May 5, 2022

United statesKelsey kirkMichelle greenblattBeth delgiaccoLuc truyenCatherine broomeDrug administrationExchange commissionGeorgetown university lombardi comprehensive cancer centerInternational working groupImmunology innovation programGlobenewswire incAssociate professorUniversity lombardi comprehensive cancer centerPrincipal investigatorWorking group

vimarsana © 2020. All Rights Reserved.